FDA OKs Fluocinolone Intravitreal Implant (Yutiq) for Uveitis FDA OKs Fluocinolone Intravitreal Implant (Yutiq) for Uveitis

In clinical trials, Yutiq significantly reduced recurrence rates at 6 and 12 months following treatment compared with sham treatment in patients with chronic, noninfectious posterior segment uveitis.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news